68 results about "Pollakisuria" patented technology

(1) A preventive and / or a remedy for lower urinary tract diseases such as inflammation in the lower urinary tract, cystitis (interstitial cystitis, etc.) and urethritis; (2) an agent for improving bladder compliance and / or bladder capacity; and (3) an agent for protecting bladder mucosa and / or bladder epithelial cells and / or promoting the regeneration thereof; each containing an EP4 agonist. An EP4 agonist is useful in ameliorating symptoms of lower urinary tract diseases such as (1) frequent urination, (2) urgency of urination, (3) pain in the reproductive organs and / or lower urinary tract (for example, bladder pain, urinary tract pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and / or (4) discomfort in the reproductive organs and / or lower urinary tract. Among all, a selective EP4 agonist is useful as a preventive and / or remedy for lower urinary tract diseases having no side effect.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The present invention relates to a phenyl or heteroaryl amino alkane derivatives which are useful as an active ingredient of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases also is alleviated by treatment with an IP receptor antagonist.

It is intended to provide a morphinan derivative represented by the following general formula (I): (I) wherein R<1> represents methyl, cyclopropylmethyl, etc.; R<2> and R<3> represent each hydroxy, methoxy, acetoxy, etc.; Y and Z represent each a valence bond, -(C=O)-, etc.; X represents a C2-5 carbon chain constituting a part of the cyclic structure (wherein one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen); (R<4>)k represents an optionally substituted fused benzene ring, carbonyl, etc.; R<9> represents hydrogen, etc.; R<10> and R<11> may be bonded together to form -O-; and R<6> represents hydrogen, etc.The above-described compound is useful as a novel remedy or preventive for urinary frequency or urinary incontinence showing an isolated side effect. Moreover, it is useful in a method for treating or preventing the above diseases and utilization for these diseases.

The invention belongs to the technical field of medicaments, and in particular relates to a medicine for treating urinary tract infection. The main active component of the medicine disclosed by the invention is polysaccharide extracted from caryophyllaceae vaccaria segetalis (Neck.) Garcke. The polysaccharide in the invention is from vaccaria segetalis (Neck.) Garcke seeds. A method for preparingthe vaccaria segetalis (Neck.) Garcke polysaccharide and vaccaria segetalis (Neck.) Garcke polysaccharide medicine composition provided by the invention is simple and effective, and capable of being prepared into a variety of common oral forms, such as solid, liquid and the like. The medicine disclosed by the invention is mainly used for treating the urinary tract infection as well as frequent micturition, urgent urination and odynuria caused by diabetes. Compared with the traditional medicines, the medicine disclosed by the invention has an obvious curative effect, low recurrence rate and notoxic and side effects, and the product quality is stable and controllable.

[Object] To provide a therapeutic and / or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action.[Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and / or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

An N-phenylarylsulfonylamide compound of formula (I) (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E2 receptor, especially an EP1 subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and / or lower urinary tract disease syndrome or an antineoplastic agent.

The invention relates to a traditional Chinese medicine composition for treating frequent urination, urgent urination and painful urination caused by hyperplasia of prostate. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 5-25 parts of gardenia jasminoides ellis, 5-20 parts of cimicifuga foetida, 5-25 parts of polygonum aviculare, 5-20 parts of scutellaria baicalensis, 5-25 parts of fringed pink, 10-30 parts of rehmannia glutinosa libosch, 5-20 parts of rhizoma alismatis, 5-25 parts of golden cypress, 5-25 parts of bamboo leaf, 5-20 parts of medicinal cyathula root, 5-25 parts of radix scrophulariae, 5-20 parts of pericarpium citri reticulatae, 5-25 parts of yam rhizome, 10-30 parts of rhizoma atractylodis macrocephalae, 5-25 parts of rhizoma corydalis, 5-25 parts of pyrrosia lingua, 5-20 parts of codonopsis pilosula, 5-25 parts of eucommia ulmoides and 5-15 parts of liquorice. The traditional Chinese medicine composition has the effects of nourishing liver and kidney, clearing away heat and drying dampness, purging fire, removing toxin, nourishing yin, promoting the secretion of saliva or body fluid, and activating blood circulation to dissipate blood stasis. By utilizing the traditional Chinese medicine composition, effects for treating the frequent urination, urgent urination and painful urination caused by the benign prostatic hyperplasia are significant, and the effect is reliable.